Research and Markets: Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2012

Research and Markets (http://www.researchandmarkets.com/research/5j2d99/posttraumatic) has announced the addition of Global Markets Direct's new report "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2012" to their offering.

'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD).

Scope

- A snapshot of the global therapeutic scenario for Post-Traumatic Stress Disorder (PTSD).

- A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Involved in Post-Traumatic Stress Disorder (PTSD) Therapeutics Development

• Nanotherapeutics, Inc.
• Addex Pharmaceuticals
• Catalyst Pharmaceutical Partners, Inc.
• Biotie Therapies Corp.
• NeuroNascent, Inc.
• Azevan Pharmaceuticals, Inc.
• Marinus Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/5j2d99/posttraumatic

Source: Global Markets Direct